SE0201943D0 - New use - Google Patents

New use

Info

Publication number
SE0201943D0
SE0201943D0 SE0201943A SE0201943A SE0201943D0 SE 0201943 D0 SE0201943 D0 SE 0201943D0 SE 0201943 A SE0201943 A SE 0201943A SE 0201943 A SE0201943 A SE 0201943A SE 0201943 D0 SE0201943 D0 SE 0201943D0
Authority
SE
Sweden
Prior art keywords
antagonists
treatment
glutamate receptor
metabotropic glutamate
new use
Prior art date
Application number
SE0201943A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Lehmann
Jan Mattsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0201943(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201943A priority Critical patent/SE0201943D0/xx
Publication of SE0201943D0 publication Critical patent/SE0201943D0/xx
Priority to CA2489730A priority patent/CA2489730C/en
Priority to ES03731333T priority patent/ES2304510T3/es
Priority to DK03731333T priority patent/DK1513525T3/da
Priority to BR0311759-6A priority patent/BR0311759A/pt
Priority to JP2004515703A priority patent/JP4683920B2/ja
Priority to DE60320990T priority patent/DE60320990D1/de
Priority to MXPA04012659A priority patent/MXPA04012659A/es
Priority to AT03731333T priority patent/ATE395059T1/de
Priority to PL03372186A priority patent/PL372186A1/xx
Priority to CNB038141760A priority patent/CN100430056C/zh
Priority to AU2003241585A priority patent/AU2003241585B2/en
Priority to EP03731333A priority patent/EP1513525B1/en
Priority to US10/517,869 priority patent/US7964609B2/en
Priority to UA20041210177A priority patent/UA81627C2/ru
Priority to NZ536559A priority patent/NZ536559A/en
Priority to PT03731333T priority patent/PT1513525E/pt
Priority to RU2005101411/15A priority patent/RU2324484C2/ru
Priority to PCT/US2003/016223 priority patent/WO2004000316A1/en
Priority to SI200331220T priority patent/SI1513525T1/sl
Priority to IL16513804A priority patent/IL165138A0/xx
Priority to ZA200409908A priority patent/ZA200409908B/en
Priority to NO20050154A priority patent/NO20050154L/no
Priority to IS7654A priority patent/IS7654A/is
Priority to HK05107987A priority patent/HK1075833A1/xx
Priority to CY20081100527T priority patent/CY1107954T1/el
Priority to JP2010268162A priority patent/JP2011068669A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0201943A 2002-06-20 2002-06-20 New use SE0201943D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use
PCT/US2003/016223 WO2004000316A1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
SI200331220T SI1513525T1 (sl) 2002-06-20 2003-06-19 Uporaba antagonistov MGLUR5 za zdravljenje gastroezofagealne refluksne bolezni
AU2003241585A AU2003241585B2 (en) 2002-06-20 2003-06-19 Use of mGluR5 antagonists for the treatment of GERD
UA20041210177A UA81627C2 (ru) 2002-06-20 2003-06-19 Применение антагонистов mglur5 для лечения гастроэзофагеального рефлюксионного заболевания
DK03731333T DK1513525T3 (da) 2002-06-20 2003-06-19 Anvendelse af MGLUR5-antagonister til behandling af GERD
BR0311759-6A BR0311759A (pt) 2002-06-20 2003-06-19 Usos de um antagonista do receptor 5 do glutamato metabotrópico ou um sal farmaceuticamente aceitável ou um isÈmero óptico do mesmo e métodos de inibição de relaxamentos transientes do esfìncter esofagiano inferior, de tratamento da doença do refluxo gastro-esofagiano, de prevenção do refluxo, de tratamento ou prevenção da regurgitação, de doença pulmonar, da asma, de laringites crÈnicas e de administração da falta de desenvolvimento
JP2004515703A JP4683920B2 (ja) 2002-06-20 2003-06-19 Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用
DE60320990T DE60320990D1 (de) 2002-06-20 2003-06-19 Verwendung von mglur5 antagonisten zur behandlung von gastroesophagalen refluxen
MXPA04012659A MXPA04012659A (es) 2002-06-20 2003-06-19 Uso de antagonistas de mglur5 para el tratamiento de gerd.
AT03731333T ATE395059T1 (de) 2002-06-20 2003-06-19 Verwendung von mglur5 antagonisten zur behandlung von gastroesophagalen refluxen
PL03372186A PL372186A1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
CNB038141760A CN100430056C (zh) 2002-06-20 2003-06-19 Mglur5拮抗剂在制备治疗gerd的药物中的用途
CA2489730A CA2489730C (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
EP03731333A EP1513525B1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
US10/517,869 US7964609B2 (en) 2002-06-20 2003-06-19 Use of mGluR5 antagonists for the treatment of gerd
ES03731333T ES2304510T3 (es) 2002-06-20 2003-06-19 Uso de antagonistas de mglur5 para el tratamiento de gerd.
NZ536559A NZ536559A (en) 2002-06-20 2003-06-19 Use of a metabotropic glutamate receptor 5 antagonist for the treatment of gastro-esphageal reflux disease
PT03731333T PT1513525E (pt) 2002-06-20 2003-06-19 Utilização de antagonistas de mglur5 para o tratamento do refluxo gastroesofágico
RU2005101411/15A RU2324484C2 (ru) 2002-06-20 2003-06-19 Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты)
IL16513804A IL165138A0 (en) 2002-06-20 2004-11-10 Use of mglur5 antagonists for the treatment of gerd
ZA200409908A ZA200409908B (en) 2002-06-20 2004-12-07 Use of MgIuR5 antagonists for the treatment of GERD
NO20050154A NO20050154L (no) 2002-06-20 2005-01-11 Anvendelse av MGLUR5-antagonister til behandling av GERD
IS7654A IS7654A (is) 2002-06-20 2005-01-19 Notkun MGLUR5 mótlyfja til meðhöndlunar á maga-vélindis-bakflæðissjúkdómum
HK05107987A HK1075833A1 (en) 2002-06-20 2005-09-12 Use of mglur5 antagonists for the treatment of gerd
CY20081100527T CY1107954T1 (el) 2002-06-20 2008-05-21 Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd
JP2010268162A JP2011068669A (ja) 2002-06-20 2010-12-01 Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use

Publications (1)

Publication Number Publication Date
SE0201943D0 true SE0201943D0 (sv) 2002-06-20

Family

ID=20288301

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use

Country Status (25)

Country Link
EP (1) EP1513525B1 (xx)
JP (2) JP4683920B2 (xx)
CN (1) CN100430056C (xx)
AT (1) ATE395059T1 (xx)
AU (1) AU2003241585B2 (xx)
BR (1) BR0311759A (xx)
CA (1) CA2489730C (xx)
CY (1) CY1107954T1 (xx)
DE (1) DE60320990D1 (xx)
DK (1) DK1513525T3 (xx)
ES (1) ES2304510T3 (xx)
HK (1) HK1075833A1 (xx)
IL (1) IL165138A0 (xx)
IS (1) IS7654A (xx)
MX (1) MXPA04012659A (xx)
NO (1) NO20050154L (xx)
NZ (1) NZ536559A (xx)
PL (1) PL372186A1 (xx)
PT (1) PT1513525E (xx)
RU (1) RU2324484C2 (xx)
SE (1) SE0201943D0 (xx)
SI (1) SI1513525T1 (xx)
UA (1) UA81627C2 (xx)
WO (1) WO2004000316A1 (xx)
ZA (1) ZA200409908B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
RU2381226C2 (ru) * 2004-02-18 2010-02-10 Астразенека Аб Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
CN1934097A (zh) * 2004-02-18 2007-03-21 阿斯利康(瑞典)有限公司 炔基化哌嗪化合物及其作为代谢型谷氨酸受体拮抗剂的应用
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
MX2008012413A (es) * 2006-03-29 2008-10-07 Hoffmann La Roche Derivados de piridina y pirimidina como antagonistas del receptor metabotropico de glutamato 2 (mglur2).
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
JP2008245225A (ja) * 2007-03-29 2008-10-09 Kddi Corp 波長パス経路決定装置、波長パス設定制御システム及びプログラム
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
CN102131503A (zh) 2008-06-30 2011-07-20 诺瓦提斯公司 用于治疗帕金森病的包含mGluR调节剂的组合产品
US20120157464A1 (en) 2009-07-23 2012-06-21 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment or prevention of ataxia
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
BR112012033290A2 (pt) 2010-06-24 2016-11-22 Novartis Ag uso de 1h-quinazolina-2,4-dionas
JP2014503568A (ja) 2011-01-27 2014-02-13 ノバルティス アーゲー ニコチン酸アセチルコリン受容体α７活性化因子の使用
EP2753331A1 (en) 2011-09-07 2014-07-16 Novartis AG Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
WO2014111751A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
BR112015016992A8 (pt) 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594424B2 (en) * 1986-01-03 1990-03-08 University Of Melbourne, The Gastro-oesophageal reflux composition
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
JP2002515448A (ja) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン 食道逆流病の処置法
NZ517221A (en) * 1999-08-19 2004-01-30 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Also Published As

Publication number Publication date
ATE395059T1 (de) 2008-05-15
BR0311759A (pt) 2005-03-08
ZA200409908B (en) 2006-08-30
IS7654A (is) 2005-01-19
ES2304510T3 (es) 2008-10-16
EP1513525A1 (en) 2005-03-16
WO2004000316A1 (en) 2003-12-31
PT1513525E (pt) 2008-06-24
DK1513525T3 (da) 2008-08-11
RU2005101411A (ru) 2005-07-10
EP1513525B1 (en) 2008-05-14
CA2489730A1 (en) 2003-12-31
JP4683920B2 (ja) 2011-05-18
JP2011068669A (ja) 2011-04-07
CA2489730C (en) 2011-11-22
CY1107954T1 (el) 2013-09-04
UA81627C2 (ru) 2008-01-25
DE60320990D1 (de) 2008-06-26
RU2324484C2 (ru) 2008-05-20
MXPA04012659A (es) 2006-05-25
SI1513525T1 (sl) 2008-08-31
HK1075833A1 (en) 2005-12-30
IL165138A0 (en) 2005-12-18
NZ536559A (en) 2007-08-31
NO20050154L (no) 2005-01-11
AU2003241585A1 (en) 2004-01-06
PL372186A1 (en) 2005-07-11
CN100430056C (zh) 2008-11-05
AU2003241585B2 (en) 2009-06-25
CN1662235A (zh) 2005-08-31
JP2006507225A (ja) 2006-03-02

Similar Documents

Publication Publication Date Title
CY1107954T1 (el) Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd
ATE301649T1 (de) Furan and thiophen derivate die menschliche peroxisome proliferator aktivierte receptoren aktivieren
ATE345128T1 (de) Modulatoren der peroxisom-proliferator- aktivierten rezeptoren (ppar)
TW200716520A (en) 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
CY1110863T1 (el) Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
DK1210344T3 (da) Heteropolycykliske forbindelser og anvendelser deraf som metabotrope glutamatreceptorantagonister
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
ATE475640T1 (de) Antagonisten des opioidrezeptors
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
ATE399164T1 (de) Antagonisten des opioidrezeptors
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
NO20075209L (no) Substituerte aryl 1,4-pyrazinderivater
DE60324357D1 (de) Zuführung eines Entwicklerpulvers ohne Klumpenbildung
BR0309764A (pt) Antagonistas de bombesina
ATE399175T1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
MXPA04004774A (es) Nuevo uso para tratamiento de enfermedad de reflujo gastroesofagico.
BR0108867A (pt) Antagonistas de receptor il-8
SE0303492D0 (sv) New use VII
RS100104A (xx) 1,3-diaza-dibenzoazuleni kao inhibitori stvaranja faktora tumorske nekroze i međuproizvodi za njihovo pripremanje
SE0201939D0 (sv) New combination
PE20020052A1 (es) Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato